AU2007289168A1 - Radioimaging moieties coupled to peptidase-binding moieties for imaging tissues and organs that express peptidases - Google Patents

Radioimaging moieties coupled to peptidase-binding moieties for imaging tissues and organs that express peptidases Download PDF

Info

Publication number: AU2007289168A1
Authority: AU; Australia
Prior art keywords: compound; carboxypeptidase; organs; mammal; peptidase
Prior art date: 2006-08-29
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU2007289168A

Other languages

English (en)

Inventor

J. W. Babich

W. C. Eckelman

F. J. Femia

Craig Zimmerman

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Molecular Insight Pharmaceuticals Inc

Original Assignee

Molecular Insight Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-08-29

Filing date

2007-08-29

Publication date

2008-03-06

2007-08-29 Application filed by Molecular Insight Pharmaceuticals Inc filed Critical Molecular Insight Pharmaceuticals Inc

2008-03-06 Publication of AU2007289168A1 publication Critical patent/AU2007289168A1/en

Status Abandoned legal-status Critical Current

Links

102000035195 Peptidases Human genes 0.000 title claims description 44
108091005804 Peptidases Proteins 0.000 title claims description 44
235000019833 protease Nutrition 0.000 title claims description 40
210000000056 organ Anatomy 0.000 title claims description 31
230000027455 binding Effects 0.000 title claims description 29
238000003384 imaging method Methods 0.000 title claims description 25
238000000034 method Methods 0.000 claims description 59
150000001875 compounds Chemical class 0.000 claims description 56
210000001519 tissue Anatomy 0.000 claims description 56
108010007859 Lisinopril Proteins 0.000 claims description 42
229960002394 lisinopril Drugs 0.000 claims description 42
RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 claims description 42
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 25
210000004072 lung Anatomy 0.000 claims description 24
239000003112 inhibitor Substances 0.000 claims description 21
102000005367 Carboxypeptidases Human genes 0.000 claims description 13
108010006303 Carboxypeptidases Proteins 0.000 claims description 13
239000003446 ligand Substances 0.000 claims description 12
108010058255 Carboxypeptidase H Proteins 0.000 claims description 11
108010080937 Carboxypeptidases A Proteins 0.000 claims description 11
102000000496 Carboxypeptidases A Human genes 0.000 claims description 11
206010019280 Heart failures Diseases 0.000 claims description 11
108090000018 Carboxypeptidase D Proteins 0.000 claims description 9
102100032378 Carboxypeptidase E Human genes 0.000 claims description 9
108010085169 Lysine carboxypeptidase Proteins 0.000 claims description 9
108010053786 carboxypeptidase Z Proteins 0.000 claims description 9
230000014509 gene expression Effects 0.000 claims description 9
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
102100032407 Carboxypeptidase D Human genes 0.000 claims description 8
102100021953 Carboxypeptidase Z Human genes 0.000 claims description 8
150000001412 amines Chemical class 0.000 claims description 8
230000001575 pathological effect Effects 0.000 claims description 8
229910052702 rhenium Inorganic materials 0.000 claims description 8
229910052751 metal Inorganic materials 0.000 claims description 7
239000002184 metal Substances 0.000 claims description 7
230000003439 radiotherapeutic effect Effects 0.000 claims description 7
108090000087 Carboxypeptidase B Proteins 0.000 claims description 6
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 6
-1 isoquinoline amine Chemical class 0.000 claims description 6
229910052760 oxygen Inorganic materials 0.000 claims description 6
210000002966 serum Anatomy 0.000 claims description 6
102100035024 Carboxypeptidase B Human genes 0.000 claims description 5
108090000007 Carboxypeptidase M Proteins 0.000 claims description 5
125000003118 aryl group Chemical group 0.000 claims description 5
229960000830 captopril Drugs 0.000 claims description 5
FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims description 5
WUAPFZMCVAUBPE-UHFFFAOYSA-N rhenium atom Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 claims description 5
WUAPFZMCVAUBPE-NJFSPNSNSA-N 188Re Chemical compound [188Re] WUAPFZMCVAUBPE-NJFSPNSNSA-N 0.000 claims description 4
102100032936 Carboxypeptidase M Human genes 0.000 claims description 4
108010066671 Enalaprilat Proteins 0.000 claims description 4
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 4
239000004472 Lysine Substances 0.000 claims description 4
206010028980 Neoplasm Diseases 0.000 claims description 4
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 4
229910052757 nitrogen Inorganic materials 0.000 claims description 4
238000012634 optical imaging Methods 0.000 claims description 4
239000001301 oxygen Substances 0.000 claims description 4
239000012217 radiopharmaceutical Substances 0.000 claims description 4
229940121896 radiopharmaceutical Drugs 0.000 claims description 4
230000002799 radiopharmaceutical effect Effects 0.000 claims description 4
WUAPFZMCVAUBPE-IGMARMGPSA-N rhenium-186 Chemical compound [186Re] WUAPFZMCVAUBPE-IGMARMGPSA-N 0.000 claims description 4
229910052713 technetium Inorganic materials 0.000 claims description 4
102100030612 Mast cell carboxypeptidase A Human genes 0.000 claims description 3
101710119290 Mast cell carboxypeptidase A Proteins 0.000 claims description 3
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
150000004697 chelate complex Chemical class 0.000 claims description 3
230000005764 inhibitory process Effects 0.000 claims description 3
AWJUIBRHMBBTKR-UHFFFAOYSA-N iso-quinoline Natural products C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 claims description 3
230000004044 response Effects 0.000 claims description 3
229910052717 sulfur Inorganic materials 0.000 claims description 3
239000011593 sulfur Substances 0.000 claims description 3
238000002560 therapeutic procedure Methods 0.000 claims description 3
201000001320 Atherosclerosis Diseases 0.000 claims description 2
208000031229 Cardiomyopathies Diseases 0.000 claims description 2
102000005593 Endopeptidases Human genes 0.000 claims description 2
108010059378 Endopeptidases Proteins 0.000 claims description 2
102000018389 Exopeptidases Human genes 0.000 claims description 2
108010091443 Exopeptidases Proteins 0.000 claims description 2
206010061218 Inflammation Diseases 0.000 claims description 2
208000019693 Lung disease Diseases 0.000 claims description 2
208000001647 Renal Insufficiency Diseases 0.000 claims description 2
206010062237 Renal impairment Diseases 0.000 claims description 2
229910052799 carbon Inorganic materials 0.000 claims description 2
229940066758 endopeptidases Drugs 0.000 claims description 2
230000004054 inflammatory process Effects 0.000 claims description 2
230000005977 kidney dysfunction Effects 0.000 claims description 2
201000006370 kidney failure Diseases 0.000 claims description 2
238000012544 monitoring process Methods 0.000 claims description 2
210000005084 renal tissue Anatomy 0.000 claims description 2
241000124008 Mammalia Species 0.000 claims 22
GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical group [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 claims 4
125000000623 heterocyclic group Chemical group 0.000 claims 4
229910052739 hydrogen Inorganic materials 0.000 claims 4
229940056501 technetium 99m Drugs 0.000 claims 4
125000003545 alkoxy group Chemical group 0.000 claims 3
150000001408 amides Chemical class 0.000 claims 3
125000004429 atom Chemical group 0.000 claims 3
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 3
125000004434 sulfur atom Chemical group 0.000 claims 3
NVXFXLSOGLFXKQ-JMSVASOKSA-N (2s)-1-[(2r,4r)-5-ethoxy-2,4-dimethyl-5-oxopentanoyl]-2,3-dihydroindole-2-carboxylic acid Chemical compound C1=CC=C2N(C(=O)[C@H](C)C[C@@H](C)C(=O)OCC)[C@H](C(O)=O)CC2=C1 NVXFXLSOGLFXKQ-JMSVASOKSA-N 0.000 claims 2
QIJLJZOGPPQCOG-NFAWXSAZSA-N (2s)-1-[(2s)-3-[(2r)-2-(cyclohexanecarbonylamino)propanoyl]sulfanyl-2-methylpropanoyl]pyrrolidine-2-carboxylic acid Chemical compound N([C@H](C)C(=O)SC[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)C(=O)C1CCCCC1 QIJLJZOGPPQCOG-NFAWXSAZSA-N 0.000 claims 2
BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 claims 2
FHHHOYXPRDYHEZ-COXVUDFISA-N Alacepril Chemical compound CC(=O)SC[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 FHHHOYXPRDYHEZ-COXVUDFISA-N 0.000 claims 2
XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 claims 2
IFYLTXNCFVRALQ-OALUTQOASA-N Ceronapril Chemical compound O([C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)P(O)(=O)CCCCC1=CC=CC=C1 IFYLTXNCFVRALQ-OALUTQOASA-N 0.000 claims 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
108010061435 Enalapril Proteins 0.000 claims 2
UWWDHYUMIORJTA-HSQYWUDLSA-N Moexipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC(OC)=C(OC)C=C2C1)C(O)=O)CC1=CC=CC=C1 UWWDHYUMIORJTA-HSQYWUDLSA-N 0.000 claims 2
VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 claims 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 2
229950007884 alacepril Drugs 0.000 claims 2
125000000217 alkyl group Chemical group 0.000 claims 2
YLFIGGHWWPSIEG-UHFFFAOYSA-N aminoxyl Chemical compound [O]N YLFIGGHWWPSIEG-UHFFFAOYSA-N 0.000 claims 2
229960004530 benazepril Drugs 0.000 claims 2
239000004202 carbamide Substances 0.000 claims 2
229950005749 ceronapril Drugs 0.000 claims 2
229960005025 cilazapril Drugs 0.000 claims 2
HHHKFGXWKKUNCY-FHWLQOOXSA-N cilazapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N2[C@@H](CCCN2CCC1)C(O)=O)=O)CC1=CC=CC=C1 HHHKFGXWKKUNCY-FHWLQOOXSA-N 0.000 claims 2
229960005227 delapril Drugs 0.000 claims 2
WOUOLAUOZXOLJQ-MBSDFSHPSA-N delapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N(CC(O)=O)C1CC2=CC=CC=C2C1)CC1=CC=CC=C1 WOUOLAUOZXOLJQ-MBSDFSHPSA-N 0.000 claims 2
229960000873 enalapril Drugs 0.000 claims 2
GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 claims 2
229960002680 enalaprilat Drugs 0.000 claims 2
LZFZMUMEGBBDTC-QEJZJMRPSA-N enalaprilat (anhydrous) Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 LZFZMUMEGBBDTC-QEJZJMRPSA-N 0.000 claims 2
229960002490 fosinopril Drugs 0.000 claims 2
239000001257 hydrogen Substances 0.000 claims 2
229960001195 imidapril Drugs 0.000 claims 2
KLZWOWYOHUKJIG-BPUTZDHNSA-N imidapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1C(N(C)C[C@H]1C(O)=O)=O)CC1=CC=CC=C1 KLZWOWYOHUKJIG-BPUTZDHNSA-N 0.000 claims 2
229960005170 moexipril Drugs 0.000 claims 2
229950006549 moveltipril Drugs 0.000 claims 2
229950008492 pentopril Drugs 0.000 claims 2
229960002582 perindopril Drugs 0.000 claims 2
IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 claims 2
229960001455 quinapril Drugs 0.000 claims 2
JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 claims 2
229960003401 ramipril Drugs 0.000 claims 2
HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 claims 2
BSHDUMDXSRLRBI-JOYOIKCWSA-N rentiapril Chemical compound SCCC(=O)N1[C@H](C(=O)O)CS[C@@H]1C1=CC=CC=C1O BSHDUMDXSRLRBI-JOYOIKCWSA-N 0.000 claims 2
229950010098 rentiapril Drugs 0.000 claims 2
229960002909 spirapril Drugs 0.000 claims 2
HRWCVUIFMSZDJS-SZMVWBNQSA-N spirapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2(C1)SCCS2)C(O)=O)CC1=CC=CC=C1 HRWCVUIFMSZDJS-SZMVWBNQSA-N 0.000 claims 2
108700035424 spirapril Proteins 0.000 claims 2
229960004084 temocapril Drugs 0.000 claims 2
FIQOFIRCTOWDOW-BJLQDIEVSA-N temocapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C[C@H](SC1)C=1SC=CC=1)=O)CC1=CC=CC=C1 FIQOFIRCTOWDOW-BJLQDIEVSA-N 0.000 claims 2
229960002051 trandolapril Drugs 0.000 claims 2
229960002769 zofenopril Drugs 0.000 claims 2
IAIDUHCBNLFXEF-MNEFBYGVSA-N zofenopril Chemical compound C([C@@H](C)C(=O)N1[C@@H](C[C@@H](C1)SC=1C=CC=CC=1)C(O)=O)SC(=O)C1=CC=CC=C1 IAIDUHCBNLFXEF-MNEFBYGVSA-N 0.000 claims 2
JOZSYOPADROCMP-UHFFFAOYSA-N 1,3-thiazol-2-ylmethanamine Chemical compound NCC1=NC=CS1 JOZSYOPADROCMP-UHFFFAOYSA-N 0.000 claims 1
PUWQSHKAAXWXLU-UHFFFAOYSA-N 2-(1,3-thiazol-2-ylmethylamino)acetic acid Chemical compound OC(=O)CNCC1=NC=CS1 PUWQSHKAAXWXLU-UHFFFAOYSA-N 0.000 claims 1
ZCDWQZLKHOOWMM-UHFFFAOYSA-N 2-(isoquinolin-3-ylmethylamino)acetic acid Chemical compound C1=CC=C2C=NC(CNCC(=O)O)=CC2=C1 ZCDWQZLKHOOWMM-UHFFFAOYSA-N 0.000 claims 1
MDMCWJVDDJDEGI-UHFFFAOYSA-N 2-(pyridin-2-ylmethylazaniumyl)acetate Chemical compound OC(=O)CNCC1=CC=CC=N1 MDMCWJVDDJDEGI-UHFFFAOYSA-N 0.000 claims 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
230000003143 atherosclerotic effect Effects 0.000 claims 1
208000035269 cancer or benign tumor Diseases 0.000 claims 1
125000004432 carbon atom Chemical group C* 0.000 claims 1
239000002738 chelating agent Substances 0.000 claims 1
150000002148 esters Chemical class 0.000 claims 1
210000005003 heart tissue Anatomy 0.000 claims 1
125000001072 heteroaryl group Chemical group 0.000 claims 1
125000005842 heteroatom Chemical group 0.000 claims 1
125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
230000004968 inflammatory condition Effects 0.000 claims 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
230000001613 neoplastic effect Effects 0.000 claims 1
125000000547 substituted alkyl group Chemical group 0.000 claims 1
GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical group [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 claims 1
102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 49
108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 49
UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 48
239000000758 substrate Substances 0.000 description 48
102000004190 Enzymes Human genes 0.000 description 34
108090000790 Enzymes Proteins 0.000 description 34
229940088598 enzyme Drugs 0.000 description 34
230000000694 effects Effects 0.000 description 29
238000012360 testing method Methods 0.000 description 21
238000006243 chemical reaction Methods 0.000 description 20
241000700159 Rattus Species 0.000 description 17
238000003556 assay Methods 0.000 description 16
238000001727 in vivo Methods 0.000 description 15
239000000523 sample Substances 0.000 description 15
241001465754 Metazoa Species 0.000 description 13
230000002401 inhibitory effect Effects 0.000 description 13
238000002347 injection Methods 0.000 description 13
239000007924 injection Substances 0.000 description 13
108090000765 processed proteins & peptides Proteins 0.000 description 13
239000000243 solution Substances 0.000 description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
102000005572 Cathepsin A Human genes 0.000 description 11
108010059081 Cathepsin A Proteins 0.000 description 11
QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
239000000203 mixture Substances 0.000 description 10
235000018102 proteins Nutrition 0.000 description 10
102000004169 proteins and genes Human genes 0.000 description 10
108090000623 proteins and genes Proteins 0.000 description 10
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
239000000872 buffer Substances 0.000 description 9
238000000338 in vitro Methods 0.000 description 9
238000005481 NMR spectroscopy Methods 0.000 description 8
210000004899 c-terminal region Anatomy 0.000 description 8
239000000047 product Substances 0.000 description 8
241000283973 Oryctolagus cuniculus Species 0.000 description 7
238000004458 analytical method Methods 0.000 description 7
210000004185 liver Anatomy 0.000 description 7
102000004196 processed proteins & peptides Human genes 0.000 description 7
239000004475 Arginine Substances 0.000 description 6
238000002835 absorbance Methods 0.000 description 6
235000009697 arginine Nutrition 0.000 description 6
210000004369 blood Anatomy 0.000 description 6
239000008280 blood Substances 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
238000002603 single-photon emission computed tomography Methods 0.000 description 6
150000003384 small molecules Chemical class 0.000 description 6
239000005541 ACE inhibitor Substances 0.000 description 5
108090000012 Carboxypeptidase T Proteins 0.000 description 5
229940024606 amino acid Drugs 0.000 description 5
235000001014 amino acid Nutrition 0.000 description 5
150000001413 amino acids Chemical class 0.000 description 5
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 5
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 5
238000004364 calculation method Methods 0.000 description 5
230000003247 decreasing effect Effects 0.000 description 5
238000004128 high performance liquid chromatography Methods 0.000 description 5
238000006460 hydrolysis reaction Methods 0.000 description 5
238000011534 incubation Methods 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
239000000700 radioactive tracer Substances 0.000 description 5
QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
CCLJGZGVIQBNDH-HNNXBMFYSA-N (2s)-2-[(2-benzamidoacetyl)amino]-3-phenylpropanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)CNC(=O)C=1C=CC=CC=1)C1=CC=CC=C1 CCLJGZGVIQBNDH-HNNXBMFYSA-N 0.000 description 4
GFLCPYUSPYXNBV-NSHDSACASA-N (2s)-2-[(2-benzamidoacetyl)amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)CNC(=O)C1=CC=CC=C1 GFLCPYUSPYXNBV-NSHDSACASA-N 0.000 description 4
IBOXOGVHBFUSFH-PMACEKPBSA-N (2s)-4-methyl-2-[[(2s)-3-phenyl-2-(phenylmethoxycarbonylamino)propanoyl]amino]pentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)OCC=1C=CC=CC=1)C1=CC=CC=C1 IBOXOGVHBFUSFH-PMACEKPBSA-N 0.000 description 4
FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 4
206010007559 Cardiac failure congestive Diseases 0.000 description 4
QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 4
ZIAXNZCTODBCKW-UHFFFAOYSA-N TMC-95 C Natural products C12=CC=CC3=C2NC(=O)C3(O)C(O)C(C(=O)NC=CC)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(=O)C(C)CC)CC2=CC=C(O)C1=C2 ZIAXNZCTODBCKW-UHFFFAOYSA-N 0.000 description 4
239000007983 Tris buffer Substances 0.000 description 4
229960003767 alanine Drugs 0.000 description 4
125000001931 aliphatic group Chemical group 0.000 description 4
YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 description 4
230000008033 biological extinction Effects 0.000 description 4
239000003153 chemical reaction reagent Substances 0.000 description 4
230000005284 excitation Effects 0.000 description 4
OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
108010062699 gamma-Glutamyl Hydrolase Proteins 0.000 description 4
210000002216 heart Anatomy 0.000 description 4
230000007062 hydrolysis Effects 0.000 description 4
210000003734 kidney Anatomy 0.000 description 4
235000018977 lysine Nutrition 0.000 description 4
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 4
238000002156 mixing Methods 0.000 description 4
QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 description 4
239000000813 peptide hormone Substances 0.000 description 4
230000003389 potentiating effect Effects 0.000 description 4
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
239000007974 sodium acetate buffer Substances 0.000 description 4
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
UMPZRJVFKVGDHY-UHFFFAOYSA-N ClC=1OC(=O)C2=CC=CC=C2C1Cl.COC(C(NC(C=[N+]=[N-])=O)CCCC)=O Chemical compound ClC=1OC(=O)C2=CC=CC=C2C1Cl.COC(C(NC(C=[N+]=[N-])=O)CCCC)=O UMPZRJVFKVGDHY-UHFFFAOYSA-N 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
206010020772 Hypertension Diseases 0.000 description 3
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
102000006166 Metallocarboxypeptidases Human genes 0.000 description 3
108030000089 Metallocarboxypeptidases Proteins 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 3
GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
238000007398 colorimetric assay Methods 0.000 description 3
CJBJHOAVZSMMDJ-HEXNFIEUSA-N darunavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C1=CC=CC=C1 CJBJHOAVZSMMDJ-HEXNFIEUSA-N 0.000 description 3
230000034994 death Effects 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
CAYJBRBGZBCZKO-BHGBQCOSSA-N ethyl (e,4s)-4-[[(2r,5s)-2-[(4-fluorophenyl)methyl]-6-methyl-5-[(5-methyl-1,2-oxazole-3-carbonyl)amino]-4-oxoheptanoyl]amino]-5-[(3s)-2-oxopyrrolidin-3-yl]pent-2-enoate Chemical compound C([C@@H](/C=C/C(=O)OCC)NC(=O)[C@@H](CC(=O)[C@@H](NC(=O)C1=NOC(C)=C1)C(C)C)CC=1C=CC(F)=CC=1)[C@@H]1CCNC1=O CAYJBRBGZBCZKO-BHGBQCOSSA-N 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
229960003142 fosamprenavir Drugs 0.000 description 3
MLBVMOWEQCZNCC-OEMFJLHTSA-N fosamprenavir Chemical compound C([C@@H]([C@H](OP(O)(O)=O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 MLBVMOWEQCZNCC-OEMFJLHTSA-N 0.000 description 3
VKVCLXDFOQQABP-BYPYZUCNSA-N guanidinoethylmercaptosuccinic acid Chemical compound NC(=N)NCCS[C@H](C(O)=O)CC(O)=O VKVCLXDFOQQABP-BYPYZUCNSA-N 0.000 description 3
CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 description 3
210000000936 intestine Anatomy 0.000 description 3
230000004807 localization Effects 0.000 description 3
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
230000003287 optical effect Effects 0.000 description 3
229940002612 prodrug Drugs 0.000 description 3
239000000651 prodrug Substances 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 3
BTGNGJJLZOIYID-UHFFFAOYSA-N sivelestat Chemical compound C1=CC(OC(=O)C(C)(C)C)=CC=C1S(=O)(=O)NC1=CC=CC=C1C(=O)NCC(O)=O BTGNGJJLZOIYID-UHFFFAOYSA-N 0.000 description 3
238000013222 sprague-dawley male rat Methods 0.000 description 3
238000012453 sprague-dawley rat model Methods 0.000 description 3
239000000126 substance Substances 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
229950009811 ubenimex Drugs 0.000 description 3
SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 description 3
PARPWSYTROKYNG-KRWDZBQOSA-N (2s)-3-phenyl-2-[[2-[[2-(phenylmethoxycarbonylamino)acetyl]amino]acetyl]amino]propanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)CNC(=O)CNC(=O)OCC=1C=CC=CC=1)C1=CC=CC=C1 PARPWSYTROKYNG-KRWDZBQOSA-N 0.000 description 2
LPIARALSGDVZEP-SJVNDZIOSA-N (3s)-3-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-4-oxobutanoic acid Chemical compound OC(=O)C[C@@H](C=O)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(C)=O)CC1=CC=C(O)C=C1 LPIARALSGDVZEP-SJVNDZIOSA-N 0.000 description 2
XLUMOZQZGPJGTL-ROUUACIJSA-N (4s)-5-[[(1s)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]-5-oxo-4-(phenylmethoxycarbonylamino)pentanoic acid Chemical compound N([C@@H](CCC(=O)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C(=O)OCC1=CC=CC=C1 XLUMOZQZGPJGTL-ROUUACIJSA-N 0.000 description 2
CXAGHAZMQSCAKJ-WAHHBDPQSA-N (4s,7s)-n-[(2r,3s)-2-ethoxy-5-oxooxolan-3-yl]-7-(isoquinoline-1-carbonylamino)-6,10-dioxo-2,3,4,7,8,9-hexahydro-1h-pyridazino[1,2-a]diazepine-4-carboxamide Chemical compound CCO[C@@H]1OC(=O)C[C@@H]1NC(=O)[C@H]1N(C(=O)[C@H](CCC2=O)NC(=O)C=3C4=CC=CC=C4C=CN=3)N2CCC1 CXAGHAZMQSCAKJ-WAHHBDPQSA-N 0.000 description 2
FPIGOBKNDYAZTP-UHFFFAOYSA-N 1,2-epoxy-3-(4-nitrophenoxy)propane Chemical compound C1=CC([N+](=O)[O-])=CC=C1OCC1OC1 FPIGOBKNDYAZTP-UHFFFAOYSA-N 0.000 description 2
KXZQYLBVMZGIKC-UHFFFAOYSA-N 1-pyridin-2-yl-n-(pyridin-2-ylmethyl)methanamine Chemical compound C=1C=CC=NC=1CNCC1=CC=CC=N1 KXZQYLBVMZGIKC-UHFFFAOYSA-N 0.000 description 2
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
RLFWWDJHLFCNIJ-UHFFFAOYSA-N 4-aminoantipyrine Chemical compound CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 description 2
229940090248 4-hydroxybenzoic acid Drugs 0.000 description 2
BXYXLQLWQBOEDJ-UHFFFAOYSA-N 4-methyl-2-[[2-[[2-(phenylmethoxycarbonylamino)acetyl]amino]acetyl]amino]pentanoic acid Chemical compound CC(C)CC(C(O)=O)NC(=O)CNC(=O)CNC(=O)OCC1=CC=CC=C1 BXYXLQLWQBOEDJ-UHFFFAOYSA-N 0.000 description 2
IBOXOGVHBFUSFH-UHFFFAOYSA-N 4-methyl-2-[[3-phenyl-2-(phenylmethoxycarbonylamino)propanoyl]amino]pentanoic acid Chemical compound C=1C=CC=CC=1COC(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=CC=C1 IBOXOGVHBFUSFH-UHFFFAOYSA-N 0.000 description 2
RRJCLYMGCZJLBQ-UHFFFAOYSA-N 5-amino-8-(diaminomethylideneamino)-2-[(4-hydroxyphenyl)methyl]-4-oxooctanoic acid Chemical compound NC(N)=NCCCC(N)C(=O)CC(C(O)=O)CC1=CC=C(O)C=C1 RRJCLYMGCZJLBQ-UHFFFAOYSA-N 0.000 description 2
WRDABNWSWOHGMS-UHFFFAOYSA-N AEBSF hydrochloride Chemical compound Cl.NCCC1=CC=C(S(F)(=O)=O)C=C1 WRDABNWSWOHGMS-UHFFFAOYSA-N 0.000 description 2
UMBVAPCONCILTL-MRHIQRDNSA-N Ac-Asp-Glu-Val-Asp-H Chemical compound OC(=O)C[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(C)=O UMBVAPCONCILTL-MRHIQRDNSA-N 0.000 description 2
DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
AXRYRYVKAWYZBR-UHFFFAOYSA-N Atazanavir Natural products C=1C=C(C=2N=CC=CC=2)C=CC=1CN(NC(=O)C(NC(=O)OC)C(C)(C)C)CC(O)C(NC(=O)C(NC(=O)OC)C(C)(C)C)CC1=CC=CC=C1 AXRYRYVKAWYZBR-UHFFFAOYSA-N 0.000 description 2
108010019625 Atazanavir Sulfate Proteins 0.000 description 2
VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 2
VGGGPCQERPFHOB-UHFFFAOYSA-N Bestatin Natural products CC(C)CC(C(O)=O)NC(=O)C(O)C(N)CC1=CC=CC=C1 VGGGPCQERPFHOB-UHFFFAOYSA-N 0.000 description 2
KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
101710082751 Carboxypeptidase S1 homolog A Proteins 0.000 description 2
208000024172 Cardiovascular disease Diseases 0.000 description 2
VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
108010016626 Dipeptides Proteins 0.000 description 2
RKYFKXLMWVUYJY-UHFFFAOYSA-N Fumaginone Natural products C1OC21CCC(=O)C(OC)C2C1(C)OC1CC=C(C)C RKYFKXLMWVUYJY-UHFFFAOYSA-N 0.000 description 2
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
239000007995 HEPES buffer Substances 0.000 description 2
101001122938 Homo sapiens Lysosomal protective protein Proteins 0.000 description 2
KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 description 2
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 2
102100028524 Lysosomal protective protein Human genes 0.000 description 2
241000579835 Merops Species 0.000 description 2
RJWLAIMXRBDUMH-ULQDDVLXSA-N N-Acetylleucyl-leucyl-methioninal Chemical compound CSCC[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(C)=O RJWLAIMXRBDUMH-ULQDDVLXSA-N 0.000 description 2
OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
TZYWCYJVHRLUCT-VABKMULXSA-N N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal Chemical compound CC(C)C[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1 TZYWCYJVHRLUCT-VABKMULXSA-N 0.000 description 2
239000004365 Protease Substances 0.000 description 2
229940079156 Proteasome inhibitor Drugs 0.000 description 2
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
108010036928 Thiorphan Proteins 0.000 description 2
SUJUHGSWHZTSEU-UHFFFAOYSA-N Tipranavir Natural products C1C(O)=C(C(CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)C(=O)OC1(CCC)CCC1=CC=CC=C1 SUJUHGSWHZTSEU-UHFFFAOYSA-N 0.000 description 2
229920004890 Triton X-100 Polymers 0.000 description 2
239000013504 Triton X-100 Substances 0.000 description 2
FMYKJLXRRQTBOR-BZSNNMDCSA-N acetylleucyl-leucyl-norleucinal Chemical compound CCCC[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(C)=O FMYKJLXRRQTBOR-BZSNNMDCSA-N 0.000 description 2
235000004279 alanine Nutrition 0.000 description 2
229960004601 aliskiren Drugs 0.000 description 2
KLRSDBSKUSSCGU-KRQUFFFQSA-N aliskiren fumarate Chemical compound OC(=O)\C=C\C(O)=O.COCCCOC1=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=CC=C1OC.COCCCOC1=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=CC=C1OC KLRSDBSKUSSCGU-KRQUFFFQSA-N 0.000 description 2
SRVFFFJZQVENJC-IHRRRGAJSA-N aloxistatin Chemical compound CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C SRVFFFJZQVENJC-IHRRRGAJSA-N 0.000 description 2
BCDGQXUMWHRQCB-UHFFFAOYSA-N aminoacetone Chemical compound CC(=O)CN BCDGQXUMWHRQCB-UHFFFAOYSA-N 0.000 description 2
229960001830 amprenavir Drugs 0.000 description 2
125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 2
229960003277 atazanavir Drugs 0.000 description 2
AXRYRYVKAWYZBR-GASGPIRDSA-N atazanavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)[C@@H](O)CN(CC=1C=CC(=CC=1)C=1N=CC=CC=1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C1=CC=CC=C1 AXRYRYVKAWYZBR-GASGPIRDSA-N 0.000 description 2
XFILPEOLDIKJHX-QYZOEREBSA-N batimastat Chemical compound C([C@@H](C(=O)NC)NC(=O)[C@H](CC(C)C)[C@H](CSC=1SC=CC=1)C(=O)NO)C1=CC=CC=C1 XFILPEOLDIKJHX-QYZOEREBSA-N 0.000 description 2
108010002974 benzyloxycarbonylleucyl-leucyl-leucine aldehyde Proteins 0.000 description 2
238000010256 biochemical assay Methods 0.000 description 2
238000009835 boiling Methods 0.000 description 2
JORVRJNILJXMMG-OLNQLETPSA-N brecanavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=C2OCOC2=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C(C=C1)=CC=C1OCC1=CSC(C)=N1 JORVRJNILJXMMG-OLNQLETPSA-N 0.000 description 2
239000007853 buffer solution Substances 0.000 description 2
ZTWZVMIYIIVABD-OEMFJLHTSA-N candoxatril Chemical compound C([C@@H](COCCOC)C(=O)OC=1C=C2CCCC2=CC=1)C1(C(=O)N[C@@H]2CC[C@@H](CC2)C(O)=O)CCCC1 ZTWZVMIYIIVABD-OEMFJLHTSA-N 0.000 description 2
ACZWIDANLCXHBM-HRCADAONSA-N candoxatrilat Chemical compound N([C@@H]1CC[C@@H](CC1)C(O)=O)C(=O)C1(C[C@@H](COCCOC)C(O)=O)CCCC1 ACZWIDANLCXHBM-HRCADAONSA-N 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
239000013592 cell lysate Substances 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
230000008859 change Effects 0.000 description 2
DHSUYTOATWAVLW-WFVMDLQDSA-N cilastatin Chemical compound CC1(C)C[C@@H]1C(=O)N\C(=C/CCCCSC[C@H](N)C(O)=O)C(O)=O DHSUYTOATWAVLW-WFVMDLQDSA-N 0.000 description 2
UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 2
229960005107 darunavir Drugs 0.000 description 2
230000007423 decrease Effects 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
MUCZHBLJLSDCSD-UHFFFAOYSA-N diisopropyl fluorophosphate Chemical compound CC(C)OP(F)(=O)OC(C)C MUCZHBLJLSDCSD-UHFFFAOYSA-N 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
239000003814 drug Substances 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
238000011067 equilibration Methods 0.000 description 2
238000000605 extraction Methods 0.000 description 2
229960005051 fluostigmine Drugs 0.000 description 2
229960000304 folic acid Drugs 0.000 description 2
235000019152 folic acid Nutrition 0.000 description 2
239000011724 folic acid Substances 0.000 description 2
230000004927 fusion Effects 0.000 description 2
235000013922 glutamic acid Nutrition 0.000 description 2
239000004220 glutamic acid Substances 0.000 description 2
229960002449 glycine Drugs 0.000 description 2
230000036541 health Effects 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
210000002429 large intestine Anatomy 0.000 description 2
229960003136 leucine Drugs 0.000 description 2
GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 2
KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
229950002736 marizomib Drugs 0.000 description 2
210000004165 myocardium Anatomy 0.000 description 2
YFCUZWYIPBUQBD-ZOWNYOTGSA-N n-[(3s)-7-amino-1-chloro-2-oxoheptan-3-yl]-4-methylbenzenesulfonamide;hydron;chloride Chemical compound Cl.CC1=CC=C(S(=O)(=O)N[C@@H](CCCCN)C(=O)CCl)C=C1 YFCUZWYIPBUQBD-ZOWNYOTGSA-N 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 2
LVRLSYPNFFBYCZ-VGWMRTNUSA-N omapatrilat Chemical compound C([C@H](S)C(=O)N[C@H]1CCS[C@H]2CCC[C@H](N2C1=O)C(=O)O)C1=CC=CC=C1 LVRLSYPNFFBYCZ-VGWMRTNUSA-N 0.000 description 2
229950000973 omapatrilat Drugs 0.000 description 2
230000002018 overexpression Effects 0.000 description 2
YFZOUMNUDGGHIW-UHFFFAOYSA-M p-chloromercuribenzoic acid Chemical compound OC(=O)C1=CC=C([Hg]Cl)C=C1 YFZOUMNUDGGHIW-UHFFFAOYSA-M 0.000 description 2
ZMHLUFWWWPBTIU-UHFFFAOYSA-N p-hydroxyhippuric acid Chemical compound OC(=O)CNC(=O)C1=CC=C(O)C=C1 ZMHLUFWWWPBTIU-UHFFFAOYSA-N 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
108010066738 piperastatin A Proteins 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
238000012545 processing Methods 0.000 description 2
239000003207 proteasome inhibitor Substances 0.000 description 2
RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
239000001008 quinone-imine dye Substances 0.000 description 2
230000002285 radioactive effect Effects 0.000 description 2
229960000311 ritonavir Drugs 0.000 description 2
NGWSFRIPKNWYAO-SHTIJGAHSA-N salinosporamide A Chemical compound C([C@@H]1[C@H](O)[C@]23C(=O)O[C@]2([C@H](C(=O)N3)CCCl)C)CCC=C1 NGWSFRIPKNWYAO-SHTIJGAHSA-N 0.000 description 2
229960001852 saquinavir Drugs 0.000 description 2
229950009343 sivelestat Drugs 0.000 description 2
210000002027 skeletal muscle Anatomy 0.000 description 2
210000000813 small intestine Anatomy 0.000 description 2
JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
230000009870 specific binding Effects 0.000 description 2
210000000952 spleen Anatomy 0.000 description 2
239000011550 stock solution Substances 0.000 description 2
LJJKNPQAGWVLDQ-SNVBAGLBSA-N thiorphan Chemical compound OC(=O)CNC(=O)[C@@H](CS)CC1=CC=CC=C1 LJJKNPQAGWVLDQ-SNVBAGLBSA-N 0.000 description 2
NZPXPXAGXYTROM-FYBSXPHGSA-N tipranavir Chemical compound C([C@@]1(CCC)OC(O)=C([C@H](CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)C(=O)C1)CC1=CC=CC=C1 NZPXPXAGXYTROM-FYBSXPHGSA-N 0.000 description 2
229960000838 tipranavir Drugs 0.000 description 2
SUJUHGSWHZTSEU-FYBSXPHGSA-N tipranavir Chemical compound C([C@@]1(CCC)OC(=O)C([C@H](CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)=C(O)C1)CC1=CC=CC=C1 SUJUHGSWHZTSEU-FYBSXPHGSA-N 0.000 description 2
229960001254 vildagliptin Drugs 0.000 description 2
239000011701 zinc Substances 0.000 description 2
JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
NGGMYCMLYOUNGM-UHFFFAOYSA-N (-)-fumagillin Natural products O1C(CC=C(C)C)C1(C)C1C(OC)C(OC(=O)C=CC=CC=CC=CC(O)=O)CCC21CO2 NGGMYCMLYOUNGM-UHFFFAOYSA-N 0.000 description 1
TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 1
FWPWHHUJACGNMZ-LIPLLEKLSA-N (1r,2s)-5-(1-hydroxy-2-methylpropyl)-2-methyl-7-oxa-4-azabicyclo[3.2.0]heptane-3,6-dione Chemical compound N1C(=O)[C@@H](C)[C@H]2OC(=O)C21C(O)C(C)C FWPWHHUJACGNMZ-LIPLLEKLSA-N 0.000 description 1
FWPWHHUJACGNMZ-NBBQQVJHSA-N (1s,2r,5r)-5-[(1s)-1-hydroxy-2-methylpropyl]-2-methyl-7-oxa-4-azabicyclo[3.2.0]heptane-3,6-dione Chemical compound N1C(=O)[C@H](C)[C@@H]2OC(=O)[C@@]21[C@@H](O)C(C)C FWPWHHUJACGNMZ-NBBQQVJHSA-N 0.000 description 1
FLEHQRTTWKDNGI-XTJILODYSA-N (1s,3r)-5-[(2e)-2-[(7ar)-1-[(2s)-5-(cyclopropylamino)pentan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-2-methylidenecyclohexane-1,3-diol Chemical compound C([C@H](C)C1[C@]2(CCCC(/C2CC1)=C\C=C1C[C@@H](O)C(=C)[C@@H](O)C1)C)CCNC1CC1 FLEHQRTTWKDNGI-XTJILODYSA-N 0.000 description 1
QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 1
FQRLGZIGRMSTAX-OLZOCXBDSA-N (2r,5s)-5-amino-2-benzyl-8-(diaminomethylideneamino)-4-oxooctanoic acid Chemical compound NC(N)=NCCC[C@H](N)C(=O)C[C@H](C(O)=O)CC1=CC=CC=C1 FQRLGZIGRMSTAX-OLZOCXBDSA-N 0.000 description 1
KWPACVJPAFGBEQ-IKGGRYGDSA-N (2s)-1-[(2r)-2-amino-3-phenylpropanoyl]-n-[(3s)-1-chloro-6-(diaminomethylideneamino)-2-oxohexan-3-yl]pyrrolidine-2-carboxamide Chemical compound C([C@@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)CCl)C1=CC=CC=C1 KWPACVJPAFGBEQ-IKGGRYGDSA-N 0.000 description 1
HAQIRIMIVLFYIX-ZFWWWQNUSA-N (2s)-1-[(2s)-2-aminobutanoyl]-n-butyl-2,3-dihydroindole-2-carboxamide Chemical compound C1=CC=C2N(C(=O)[C@@H](N)CC)[C@H](C(=O)NCCCC)CC2=C1 HAQIRIMIVLFYIX-ZFWWWQNUSA-N 0.000 description 1
MRXDGVXSWIXTQL-HYHFHBMOSA-N (2s)-2-[[(1s)-1-(2-amino-1,4,5,6-tetrahydropyrimidin-6-yl)-2-[[(2s)-4-methyl-1-oxo-1-[[(2s)-1-oxo-3-phenylpropan-2-yl]amino]pentan-2-yl]amino]-2-oxoethyl]carbamoylamino]-3-phenylpropanoic acid Chemical compound C([C@H](NC(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C=O)C1NC(N)=NCC1)C(O)=O)C1=CC=CC=C1 MRXDGVXSWIXTQL-HYHFHBMOSA-N 0.000 description 1
IJWCGVPEDDQUDE-YGJAXBLXSA-N (2s)-2-[[(1s)-2-[[(2s)-5-amino-1,5-dioxo-1-[[(2s)-1-oxopropan-2-yl]amino]pentan-2-yl]amino]-1-[(6s)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-2-oxoethyl]carbamoylamino]-4-methylpentanoic acid Chemical compound O=C[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)N[C@@H](CC(C)C)C(O)=O)[C@@H]1CCN=C(N)N1 IJWCGVPEDDQUDE-YGJAXBLXSA-N 0.000 description 1
UNPBSZUDTFBULK-CZCKBYKRSA-N (2s)-2-[[(2r)-2-[[(3s)-3-amino-2-oxopentanoyl]amino]-4-methylpentanoyl]-[(2s,6s)-2,6-diamino-3,7-dimethyl-5-oxooctanoyl]amino]-3-methylbutanoic acid Chemical compound CC[C@H](N)C(=O)C(=O)N[C@H](CC(C)C)C(=O)N([C@@H](C(C)C)C(O)=O)C(=O)[C@@H](N)C(C)CC(=O)[C@@H](N)C(C)C UNPBSZUDTFBULK-CZCKBYKRSA-N 0.000 description 1
JAPJOLBDXOXSKE-WQICJITCSA-N (2s)-2-[[(2s)-2-[[(e)-3-(furan-2-yl)prop-2-enoyl]amino]-3-phenylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)\C=C\C=1OC=CC=1)C1=CC=CC=C1 JAPJOLBDXOXSKE-WQICJITCSA-N 0.000 description 1
IHVRJTCVMKJNRP-IRXDYDNUSA-N (2s)-2-[[(2s)-2-[[2-[(4-hydroxybenzoyl)amino]acetyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-4-methylpentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)C=1C=CC(O)=CC=1)C1=CN=CN1 IHVRJTCVMKJNRP-IRXDYDNUSA-N 0.000 description 1
LEJTXQOVOPDGHS-YOEHRIQHSA-N (2s)-2-[[(2s)-3-phenyl-2-(phenylmethoxycarbonylamino)propanoyl]amino]propanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)OCC=1C=CC=CC=1)C1=CC=CC=C1 LEJTXQOVOPDGHS-YOEHRIQHSA-N 0.000 description 1
AXNJBMQISBJVSJ-RDBSUJKOSA-N (2s)-2-[[(2s,3r)-3-amino-2-hydroxy-4-(4-nitrophenyl)butanoyl]amino]-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=C([N+]([O-])=O)C=C1 AXNJBMQISBJVSJ-RDBSUJKOSA-N 0.000 description 1
CIMBZJOQGIUTBC-MOKVOYLWSA-N (2s)-2-[[3-amino-4-(4-azidophenyl)-2-hydroxybutanoyl]amino]-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)C(O)C(N)CC1=CC=C(N=[N+]=[N-])C=C1 CIMBZJOQGIUTBC-MOKVOYLWSA-N 0.000 description 1
LJCBAPRMNYSDOP-LVCYMWGESA-N (2s)-3-(7-carbamimidoylnaphthalen-2-yl)-2-[4-[(3s)-1-ethanimidoylpyrrolidin-3-yl]oxyphenyl]propanoic acid;hydron;chloride;pentahydrate Chemical compound O.O.O.O.O.Cl.C1N(C(=N)C)CC[C@@H]1OC1=CC=C([C@H](CC=2C=C3C=C(C=CC3=CC=2)C(N)=N)C(O)=O)C=C1 LJCBAPRMNYSDOP-LVCYMWGESA-N 0.000 description 1
KVMXOYCJJRUPKZ-RIVSHMCHSA-N (2s)-5-(diaminomethylideneamino)-2-[[(2s)-2-[[(e)-3-(furan-2-yl)prop-2-enoyl]amino]propanoyl]amino]pentanoic acid Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)\C=C\C1=CC=CO1 KVMXOYCJJRUPKZ-RIVSHMCHSA-N 0.000 description 1
BZUABSYGNBFITP-DDOQPMFUSA-N (2s)-6-amino-2-[[(2s)-2-[[(e)-3-(furan-2-yl)prop-2-enoyl]amino]propanoyl]amino]hexanoic acid Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)\C=C\C1=CC=CO1 BZUABSYGNBFITP-DDOQPMFUSA-N 0.000 description 1
SCVHJVCATBPIHN-SJCJKPOMSA-N (3s)-3-[[(2s)-2-[[2-(2-tert-butylanilino)-2-oxoacetyl]amino]propanoyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid Chemical compound N([C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)COC=1C(=C(F)C=C(F)C=1F)F)C(=O)C(=O)NC1=CC=CC=C1C(C)(C)C SCVHJVCATBPIHN-SJCJKPOMSA-N 0.000 description 1
CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 1
WKYBEGDEGRCZNF-LBTYKNIQSA-N (3s,4s)-4-[[(2s)-2-[[(3s,4s)-4-[[(2s)-2-[[(2s)-2-acetamido-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxy-6-methylheptanoyl]amino]propanoyl]amino]-3-hydroxy-6-methylheptanoic acid Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(C)=O)C(C)C WKYBEGDEGRCZNF-LBTYKNIQSA-N 0.000 description 1
NBCQBGBECVUZMK-UHFFFAOYSA-N (4-carboxyphenyl)mercury;hydrate Chemical compound O.OC(=O)C1=CC=C([Hg])C=C1 NBCQBGBECVUZMK-UHFFFAOYSA-N 0.000 description 1
CFOQGBUQTOGYKI-UHFFFAOYSA-N (4-nitrophenyl) 4-(diaminomethylideneamino)benzoate Chemical compound C1=CC(N=C(N)N)=CC=C1C(=O)OC1=CC=C([N+]([O-])=O)C=C1 CFOQGBUQTOGYKI-UHFFFAOYSA-N 0.000 description 1
PKSBDZOBYIKNGY-UHFFFAOYSA-N (4-nitrophenyl) 4-(diaminomethylideneamino)benzoate;hydrochloride Chemical compound Cl.C1=CC(N=C(N)N)=CC=C1C(=O)OC1=CC=C([N+]([O-])=O)C=C1 PKSBDZOBYIKNGY-UHFFFAOYSA-N 0.000 description 1
AXFUEWZUGAWNIX-IMNFJDCFSA-N (4S)-4-[[(2S)-2-acetamido-3-(1H-indol-3-yl)propanoyl]amino]-5-[[(2S)-1-[[(2S)-1,4-dioxobutan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound C([C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)C)C(=O)N[C@@H](CC=O)C=O)C1=CNC=N1 AXFUEWZUGAWNIX-IMNFJDCFSA-N 0.000 description 1
PTLMXCGBNCVAJC-WSMBLCCSSA-N (4S)-4-[[(2S)-2-acetamido-3-carboxypropanoyl]amino]-5-[[(2S)-1-[[(2S)-1,4-dioxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxopentanoic acid Chemical compound O=CC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(C)=O PTLMXCGBNCVAJC-WSMBLCCSSA-N 0.000 description 1
ZDTGOKPRLPBLRQ-CFZKVASOSA-N 1-ethylpyrrole-2,5-dione (Z)-3-(5-fluoro-1H-indol-3-yl)-2-sulfanylprop-2-enoic acid Chemical compound CCN1C(=O)C=CC1=O.CCN1C(=O)C=CC1=O.c1cc(F)cc2c1[nH]cc2/C=C(\S)C(=O)O ZDTGOKPRLPBLRQ-CFZKVASOSA-N 0.000 description 1
HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
HMPQTEPEMQZWQH-UHFFFAOYSA-N 2-(5-amino-6-oxo-2-phenylpyrimidin-1-yl)-n-[1-(5-tert-butyl-1,3,4-oxadiazol-2-yl)-1-hydroxy-3-methylbutan-2-yl]acetamide Chemical compound N=1N=C(C(C)(C)C)OC=1C(O)C(C(C)C)NC(=O)CN(C(C(N)=CN=1)=O)C=1C1=CC=CC=C1 HMPQTEPEMQZWQH-UHFFFAOYSA-N 0.000 description 1
YSIHYROEMJSOAS-UHFFFAOYSA-N 2-(5-amino-6-oxo-2-phenylpyrimidin-1-yl)-n-[1-(5-tert-butyl-1,3,4-oxadiazol-2-yl)-3-methyl-1-oxobutan-2-yl]acetamide Chemical compound N=1N=C(C(C)(C)C)OC=1C(=O)C(C(C)C)NC(=O)CN(C(C(N)=CN=1)=O)C=1C1=CC=CC=C1 YSIHYROEMJSOAS-UHFFFAOYSA-N 0.000 description 1
XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
LJBVKRYJJZQKGE-UHFFFAOYSA-N 2-[3-(aminomethyl)phenyl]-n-[2-fluoro-4-(2-methylsulfonylphenyl)phenyl]-5-(trifluoromethyl)pyrazole-3-carboxamide;hydrochloride Chemical compound Cl.CS(=O)(=O)C1=CC=CC=C1C(C=C1F)=CC=C1NC(=O)C1=CC(C(F)(F)F)=NN1C1=CC=CC(CN)=C1 LJBVKRYJJZQKGE-UHFFFAOYSA-N 0.000 description 1
ODUOJXZPIYUATO-UHFFFAOYSA-N 2-[[2-[(acetylthio)methyl]-1-oxo-3-phenylpropyl]amino]acetic acid (phenylmethyl) ester Chemical compound C=1C=CC=CC=1COC(=O)CNC(=O)C(CSC(=O)C)CC1=CC=CC=C1 ODUOJXZPIYUATO-UHFFFAOYSA-N 0.000 description 1
CGWBIHLHAGNJCX-UHFFFAOYSA-N 2-butylguanidine Chemical compound CCCCNC(N)=N CGWBIHLHAGNJCX-UHFFFAOYSA-N 0.000 description 1
LDSJMFGYNFIFRK-UHFFFAOYSA-N 3-azaniumyl-2-hydroxy-4-phenylbutanoate Chemical compound OC(=O)C(O)C(N)CC1=CC=CC=C1 LDSJMFGYNFIFRK-UHFFFAOYSA-N 0.000 description 1
FAXGPCHRFPCXOO-UHFFFAOYSA-N 3-hydroxy-4-[2-[[3-hydroxy-6-methyl-4-[[3-methyl-2-[[3-methyl-2-(3-methylbutanoylamino)butanoyl]amino]butanoyl]amino]heptanoyl]amino]propanoylamino]-6-methylheptanoic acid Chemical compound OC(=O)CC(O)C(CC(C)C)NC(=O)C(C)NC(=O)CC(O)C(CC(C)C)NC(=O)C(C(C)C)NC(=O)C(C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-UHFFFAOYSA-N 0.000 description 1
OLTJNTLCZYWHKR-UHFFFAOYSA-N 3-methyl-2-[[2-[[2-(phenylmethoxycarbonylamino)acetyl]amino]acetyl]amino]butanoic acid Chemical compound CC(C)C(C(O)=O)NC(=O)CNC(=O)CNC(=O)OCC1=CC=CC=C1 OLTJNTLCZYWHKR-UHFFFAOYSA-N 0.000 description 1
REPVVNYZORKKPQ-UHFFFAOYSA-N 3-oxo-3-[(1-phenyl-3-sulfanylpropan-2-yl)amino]propanoic acid Chemical compound OC(=O)CC(=O)NC(CS)CC1=CC=CC=C1 REPVVNYZORKKPQ-UHFFFAOYSA-N 0.000 description 1
ACZWIDANLCXHBM-UHFFFAOYSA-N 4-[[1-[2-carboxy-3-(2-methoxyethoxy)propyl]cyclopentanecarbonyl]amino]cyclohexane-1-carboxylic acid Chemical compound C1CC(C(O)=O)CCC1NC(=O)C1(CC(COCCOC)C(O)=O)CCCC1 ACZWIDANLCXHBM-UHFFFAOYSA-N 0.000 description 1
RASVDPMJVCEAOR-UHFFFAOYSA-N 4-[[2-[(4-fluorophenyl)methyl]-6-methyl-5-[(5-methyl-2H-1,3-oxazole-3-carbonyl)amino]-4-oxoheptanoyl]amino]-5-(2-oxopyrrolidin-3-yl)pent-2-enoic acid Chemical compound C=1C=C(F)C=CC=1CC(C(=O)NC(CC1C(NCC1)=O)C=CC(O)=O)CC(=O)C(C(C)C)NC(=O)N1COC(C)=C1 RASVDPMJVCEAOR-UHFFFAOYSA-N 0.000 description 1
SSMIFVHARFVINF-UHFFFAOYSA-N 4-amino-1,8-naphthalimide Chemical compound O=C1NC(=O)C2=CC=CC3=C2C1=CC=C3N SSMIFVHARFVINF-UHFFFAOYSA-N 0.000 description 1
SXTSBZBQQRIYCU-UHFFFAOYSA-N 4-guanidinobenzoic acid Chemical compound NC(=N)NC1=CC=C(C(O)=O)C=C1 SXTSBZBQQRIYCU-UHFFFAOYSA-N 0.000 description 1
NJGFHHXZSDLYQJ-UHFFFAOYSA-N 4-hydroxy-2,3-dihydropyran-6-one Chemical class OC1=CC(=O)OCC1 NJGFHHXZSDLYQJ-UHFFFAOYSA-N 0.000 description 1
PSGQCCSGKGJLRL-UHFFFAOYSA-N 4-methyl-2h-chromen-2-one Chemical group C1=CC=CC2=C1OC(=O)C=C2C PSGQCCSGKGJLRL-UHFFFAOYSA-N 0.000 description 1
DAFWZROYEOVJAL-UHFFFAOYSA-N 4-methylumbelliferyl-p-guanidinobenzoate hydrochloride Chemical compound Cl.C1=CC=2C(C)=CC(=O)OC=2C=C1OC(=O)C1=CC=C(N=C(N)N)C=C1 DAFWZROYEOVJAL-UHFFFAOYSA-N 0.000 description 1
TYMLOMAKGOJONV-UHFFFAOYSA-N 4-nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C=C1 TYMLOMAKGOJONV-UHFFFAOYSA-N 0.000 description 1
HNPQJYRZYQRLFN-UHFFFAOYSA-N 5-(diaminomethylideneamino)-2-(sulfanylmethyl)pentanethioic s-acid Chemical compound NC(N)=NCCCC(CS)C(S)=O HNPQJYRZYQRLFN-UHFFFAOYSA-N 0.000 description 1
LVRLSYPNFFBYCZ-UHFFFAOYSA-N 5-oxo-4-[(3-phenyl-2-sulfanylpropanoyl)amino]-2,3,4,7,8,9,10,10a-octahydropyrido[2,1-b][1,3]thiazepine-7-carboxylic acid Chemical compound O=C1N2C(C(=O)O)CCCC2SCCC1NC(=O)C(S)CC1=CC=CC=C1 LVRLSYPNFFBYCZ-UHFFFAOYSA-N 0.000 description 1
SITWEMZOJNKJCH-WDSKDSINSA-N Ala-Arg Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N SITWEMZOJNKJCH-WDSKDSINSA-N 0.000 description 1
UXOWGYHJODZGMF-QORCZRPOSA-N Aliskiren Chemical compound COCCCOC1=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=CC=C1OC UXOWGYHJODZGMF-QORCZRPOSA-N 0.000 description 1
102000004400 Aminopeptidases Human genes 0.000 description 1
108090000915 Aminopeptidases Proteins 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
108010089414 Anaphylatoxins Proteins 0.000 description 1
102400000345 Angiotensin-2 Human genes 0.000 description 1
101800000733 Angiotensin-2 Proteins 0.000 description 1
108010087765 Antipain Proteins 0.000 description 1
FQRLGZIGRMSTAX-UHFFFAOYSA-N Arphamenine A Natural products NC(N)=NCCCC(N)C(=O)CC(C(O)=O)CC1=CC=CC=C1 FQRLGZIGRMSTAX-UHFFFAOYSA-N 0.000 description 1
108030004804 Aspartic endopeptidases Proteins 0.000 description 1
102000009422 Aspartic endopeptidases Human genes 0.000 description 1
206010003497 Asphyxia Diseases 0.000 description 1
ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical group N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
VFGBXFZXJAWPOE-PEOIOWGVSA-N CCCCCC[C@H]1OC(=O)CNC(=O)[C@H]([C@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@H](C)CC)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H]1C Chemical compound CCCCCC[C@H]1OC(=O)CNC(=O)[C@H]([C@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@H](C)CC)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H]1C VFGBXFZXJAWPOE-PEOIOWGVSA-N 0.000 description 1
QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 description 1
229940121926 Calpain inhibitor Drugs 0.000 description 1
102100035037 Calpastatin Human genes 0.000 description 1
102100030613 Carboxypeptidase A1 Human genes 0.000 description 1
102100026678 Carboxypeptidase N catalytic chain Human genes 0.000 description 1
229940094918 Cathepsin L inhibitor Drugs 0.000 description 1
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
OLVPQBGMUGIKIW-UHFFFAOYSA-N Chymostatin Natural products C=1C=CC=CC=1CC(C=O)NC(=O)C(C(C)CC)NC(=O)C(C1NC(N)=NCC1)NC(=O)NC(C(O)=O)CC1=CC=CC=C1 OLVPQBGMUGIKIW-UHFFFAOYSA-N 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
102100032644 Copine-2 Human genes 0.000 description 1
229920000742 Cotton Polymers 0.000 description 1
102000004420 Creatine Kinase Human genes 0.000 description 1
108010042126 Creatine kinase Proteins 0.000 description 1
102000003950 Cysteine Endopeptidases Human genes 0.000 description 1
108090000395 Cysteine Endopeptidases Proteins 0.000 description 1
DWJXYEABWRJFSP-XOBRGWDASA-N DAPT Chemical compound N([C@@H](C)C(=O)N[C@H](C(=O)OC(C)(C)C)C=1C=CC=CC=1)C(=O)CC1=CC(F)=CC(F)=C1 DWJXYEABWRJFSP-XOBRGWDASA-N 0.000 description 1
XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
208000007342 Diabetic Nephropathies Diseases 0.000 description 1
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
IJWCGVPEDDQUDE-UHFFFAOYSA-N Elastatinal Natural products O=CC(C)NC(=O)C(CCC(N)=O)NC(=O)C(NC(=O)NC(CC(C)C)C(O)=O)C1CCN=C(N)N1 IJWCGVPEDDQUDE-UHFFFAOYSA-N 0.000 description 1
206010014561 Emphysema Diseases 0.000 description 1
108090000371 Esterases Proteins 0.000 description 1
108050001049 Extracellular proteins Proteins 0.000 description 1
BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
229940125373 Gamma-Secretase Inhibitor Drugs 0.000 description 1
VFGBXFZXJAWPOE-UHFFFAOYSA-N Globomycin Natural products CCCCCCC1OC(=O)CNC(=O)C(C(C)O)NC(=O)C(CO)NC(=O)C(C(C)CC)NC(=O)C(CC(C)C)N(C)C(=O)C1C VFGBXFZXJAWPOE-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
MMFKFJORZBJVNF-UWVGGRQHSA-N His-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CN=CN1 MMFKFJORZBJVNF-UWVGGRQHSA-N 0.000 description 1
101000772551 Homo sapiens Carboxypeptidase A1 Proteins 0.000 description 1
101000910843 Homo sapiens Carboxypeptidase N catalytic chain Proteins 0.000 description 1
101000909153 Homo sapiens Carboxypeptidase N subunit 2 Proteins 0.000 description 1
101000941754 Homo sapiens Copine-1 Proteins 0.000 description 1
101000941777 Homo sapiens Copine-2 Proteins 0.000 description 1
101000761960 Homo sapiens Cytochrome P450 11B1, mitochondrial Proteins 0.000 description 1
101000761956 Homo sapiens Cytochrome P450 11B2, mitochondrial Proteins 0.000 description 1
OHMWVDQYCQHOKS-UHFFFAOYSA-N ICC(=O)O.ICC(=O)O.ICC(=O)N Chemical compound ICC(=O)O.ICC(=O)O.ICC(=O)N OHMWVDQYCQHOKS-UHFFFAOYSA-N 0.000 description 1
208000032382 Ischaemic stroke Diseases 0.000 description 1
102000002397 Kinins Human genes 0.000 description 1
108010093008 Kinins Proteins 0.000 description 1
NJBBLOIWMSYVCQ-VZTVMPNDSA-N Kynostatin 272 Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)COC=1C2=CC=NC=C2C=CC=1)CSC)[C@H](O)C(=O)N1[C@@H](CSC1)C(=O)NC(C)(C)C)C1=CC=CC=C1 NJBBLOIWMSYVCQ-VZTVMPNDSA-N 0.000 description 1
AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
SITWEMZOJNKJCH-UHFFFAOYSA-N L-alanine-L-arginine Natural products CC(N)C(=O)NC(C(O)=O)CCCNC(N)=N SITWEMZOJNKJCH-UHFFFAOYSA-N 0.000 description 1
150000008575 L-amino acids Chemical group 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical class C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
DAQAKHDKYAWHCG-UHFFFAOYSA-N Lactacystin Natural products CC(=O)NC(C(O)=O)CSC(=O)C1(C(O)C(C)C)NC(=O)C(C)C1O DAQAKHDKYAWHCG-UHFFFAOYSA-N 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
108010090054 Membrane Glycoproteins Proteins 0.000 description 1
102000012750 Membrane Glycoproteins Human genes 0.000 description 1
108090000131 Metalloendopeptidases Proteins 0.000 description 1
102000003843 Metalloendopeptidases Human genes 0.000 description 1
102000005741 Metalloproteases Human genes 0.000 description 1
108010006035 Metalloproteases Proteins 0.000 description 1
108010051054 N-benzyloxycarbonylphenylalanylalanine Proteins 0.000 description 1
MSHZHSPISPJWHW-PVDLLORBSA-N O-(chloroacetylcarbamoyl)fumagillol Chemical compound C([C@H]([C@H]([C@@H]1[C@]2(C)[C@H](O2)CC=C(C)C)OC)OC(=O)NC(=O)CCl)C[C@@]21CO2 MSHZHSPISPJWHW-PVDLLORBSA-N 0.000 description 1
MSHZHSPISPJWHW-UHFFFAOYSA-N O-(chloroacetylcarbamoyl)fumagillol Chemical compound O1C(CC=C(C)C)C1(C)C1C(OC)C(OC(=O)NC(=O)CCl)CCC21CO2 MSHZHSPISPJWHW-UHFFFAOYSA-N 0.000 description 1
AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
QYXSCKPIFSEBSF-UHFFFAOYSA-N P(=O)(O)(O)CC(C(=O)O)CCC(=O)O.S(=O)(=O)(F)F.C1(=CC=CC=C1)C Chemical compound P(=O)(O)(O)CC(C(=O)O)CCC(=O)O.S(=O)(=O)(F)F.C1(=CC=CC=C1)C QYXSCKPIFSEBSF-UHFFFAOYSA-N 0.000 description 1
208000018262 Peripheral vascular disease Diseases 0.000 description 1
ZPHBZEQOLSRPAK-UHFFFAOYSA-N Phosphoramidon Natural products C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O ZPHBZEQOLSRPAK-UHFFFAOYSA-N 0.000 description 1
LRXVQHCIMZSTJH-UHFFFAOYSA-N Poststatin Natural products CC(C)C(N)C(=O)NC(C(C)C)C(=O)NC(CC)C(=O)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(O)=O LRXVQHCIMZSTJH-UHFFFAOYSA-N 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
108010068504 SCH6 Proteins 0.000 description 1
108091006629 SLC13A2 Proteins 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
108010000303 Secretory Proteinase Inhibitory Proteins Proteins 0.000 description 1
102000002255 Secretory Proteinase Inhibitory Proteins Human genes 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
108090000083 Serine Endopeptidases Proteins 0.000 description 1
102000003667 Serine Endopeptidases Human genes 0.000 description 1
208000005718 Stomach Neoplasms Diseases 0.000 description 1
102400000096 Substance P Human genes 0.000 description 1
101800003906 Substance P Proteins 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930195246 TMC-95 Natural products 0.000 description 1
108010065317 TMC-95A Proteins 0.000 description 1
ZIAXNZCTODBCKW-BOYGTWLISA-N TMC-95A Chemical compound O[C@@H]([C@]1(O)C(=O)NC2=C1C=CC=C21)[C@@H](C(=O)N\C=C/C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)C(=O)[C@@H](C)CC)CC2=CC=C(O)C1=C2 ZIAXNZCTODBCKW-BOYGTWLISA-N 0.000 description 1
108010065313 TMC-95B Proteins 0.000 description 1
ZIAXNZCTODBCKW-NKGUOCGVSA-N TMC-95B Chemical compound O[C@@H]([C@]1(O)C(=O)NC2=C1C=CC=C21)[C@@H](C(=O)N\C=C/C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)C(=O)[C@H](C)CC)CC2=CC=C(O)C1=C2 ZIAXNZCTODBCKW-NKGUOCGVSA-N 0.000 description 1
108010064948 TMC-95C Proteins 0.000 description 1
ZIAXNZCTODBCKW-QDRDEZGCSA-N TMC-95C Chemical compound O[C@H]([C@]1(O)C(=O)NC2=C1C=CC=C21)[C@@H](C(=O)N\C=C/C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)C(=O)[C@@H](C)CC)CC2=CC=C(O)C1=C2 ZIAXNZCTODBCKW-QDRDEZGCSA-N 0.000 description 1
108010064946 TMC-95D Proteins 0.000 description 1
ZIAXNZCTODBCKW-WYRJOJSMSA-N TMC-95D Chemical compound O[C@H]([C@]1(O)C(=O)NC2=C1C=CC=C21)[C@@H](C(=O)N\C=C/C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)C(=O)[C@H](C)CC)CC2=CC=C(O)C1=C2 ZIAXNZCTODBCKW-WYRJOJSMSA-N 0.000 description 1
241000203770 Thermoactinomyces vulgaris Species 0.000 description 1
229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
OSMJFYFZOAVCNP-KLZDYHPHSA-N Tyropeptin A Chemical compound C([C@H](NC(=O)CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)NC(CC=1C=CC(O)=CC=1)C=O)C1=CC=C(O)C=C1 OSMJFYFZOAVCNP-KLZDYHPHSA-N 0.000 description 1
229910052770 Uranium Inorganic materials 0.000 description 1
230000004156 Wnt signaling pathway Effects 0.000 description 1
NGBKFLTYGSREKK-PMACEKPBSA-N Z-Val-Phe-H Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C=O)C(=O)OCC1=CC=CC=C1 NGBKFLTYGSREKK-PMACEKPBSA-N 0.000 description 1
108010019752 ZD 8321 Proteins 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
101710204001 Zinc metalloprotease Proteins 0.000 description 1
YALIVVKJRYVKNB-GGHPKCFRSA-N [(3r,4s,5s,6r)-5-methoxy-4-[(2r,3r)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl]-1-oxaspiro[2.5]octan-6-yl] (e)-3-(3,4,5-trimethoxyphenyl)prop-2-enoate Chemical compound C([C@H]([C@H]([C@@H]1[C@]2(C)[C@H](O2)CC=C(C)C)OC)OC(=O)\C=C\C=2C=C(OC)C(OC)=C(OC)C=2)C[C@@]21CO2 YALIVVKJRYVKNB-GGHPKCFRSA-N 0.000 description 1
108010066665 acetyl-aspartyl-glutamyl-valyl-aspartal Proteins 0.000 description 1
108010038177 acetyl-tryptophyl-glutamyl-histidyl-aspartal Proteins 0.000 description 1
108010091545 acetylleucyl-leucyl-norleucinal Proteins 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
XJLATMLVMSFZBN-VYDXJSESSA-N actinonin Chemical compound CCCCC[C@H](CC(=O)NO)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1CO XJLATMLVMSFZBN-VYDXJSESSA-N 0.000 description 1
XJLATMLVMSFZBN-UHFFFAOYSA-N actinonine Natural products CCCCCC(CC(=O)NO)C(=O)NC(C(C)C)C(=O)N1CCCC1CO XJLATMLVMSFZBN-UHFFFAOYSA-N 0.000 description 1
239000012190 activator Substances 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
QFAADIRHLBXJJS-ZAZJUGBXSA-N amastatin Chemical compound CC(C)C[C@@H](N)[C@H](O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC(O)=O QFAADIRHLBXJJS-ZAZJUGBXSA-N 0.000 description 1
108010052590 amastatin Proteins 0.000 description 1
238000010976 amide bond formation reaction Methods 0.000 description 1
108010003977 aminoacylase I Proteins 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
229950006323 angiotensin ii Drugs 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 description 1
108010009669 apstatin Proteins 0.000 description 1
YVUUZAPYLPWFHE-HXFGRODQSA-N apstatin Chemical compound NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1N(C(=O)[C@@H](O)[C@H](N)CC=2C=CC=CC=2)CCC1 YVUUZAPYLPWFHE-HXFGRODQSA-N 0.000 description 1
229940030139 aptivus Drugs 0.000 description 1
KXNPVXPOPUZYGB-XYVMCAHJSA-N argatroban Chemical compound OC(=O)[C@H]1C[C@H](C)CCN1C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NC[C@H](C)C2 KXNPVXPOPUZYGB-XYVMCAHJSA-N 0.000 description 1
229960003856 argatroban Drugs 0.000 description 1
150000001484 arginines Chemical group 0.000 description 1
239000012131 assay buffer Substances 0.000 description 1
208000027697 autoimmune lymphoproliferative syndrome due to CTLA4 haploinsuffiency Diseases 0.000 description 1
238000000376 autoradiography Methods 0.000 description 1
CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
108010016899 bacitracin A Proteins 0.000 description 1
229950001858 batimastat Drugs 0.000 description 1
PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
QXXMSEVVNUSHKJ-KEKPXRHTSA-N benzyl (2s)-2-[[2-[[[(2s)-2-amino-4-methylsulfanylbutyl]disulfanyl]methyl]-3-phenylpropanoyl]amino]-3-phenylpropanoate Chemical compound N([C@@H](CC=1C=CC=CC=1)C(=O)OCC=1C=CC=CC=1)C(=O)C(CSSC[C@@H](N)CCSC)CC1=CC=CC=C1 QXXMSEVVNUSHKJ-KEKPXRHTSA-N 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
125000004057 biotinyl group Chemical class [H]N1C(=O)N([H])[C@]2([H])[C@@]([H])(SC([H])([H])[C@]12[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
239000012490 blank solution Substances 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
229960000517 boceprevir Drugs 0.000 description 1
LHHCSNFAOIFYRV-DOVBMPENSA-N boceprevir Chemical compound O=C([C@@H]1[C@@H]2[C@@H](C2(C)C)CN1C(=O)[C@@H](NC(=O)NC(C)(C)C)C(C)(C)C)NC(C(=O)C(N)=O)CC1CCC1 LHHCSNFAOIFYRV-DOVBMPENSA-N 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
229960001467 bortezomib Drugs 0.000 description 1
229950009079 brecanavir Drugs 0.000 description 1
239000001273 butane Substances 0.000 description 1
108010007877 calpain inhibitor III Proteins 0.000 description 1
108010079785 calpain inhibitors Proteins 0.000 description 1
108010044208 calpastatin Proteins 0.000 description 1
229950004548 candoxatril Drugs 0.000 description 1
229950001305 candoxatrilat Drugs 0.000 description 1
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
238000012754 cardiac puncture Methods 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
239000013522 chelant Substances 0.000 description 1
230000009920 chelation Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
208000020832 chronic kidney disease Diseases 0.000 description 1
208000022831 chronic renal failure syndrome Diseases 0.000 description 1
108010086192 chymostatin Proteins 0.000 description 1
229960004912 cilastatin Drugs 0.000 description 1
PJZPDFUUXKKDNB-KNINVFKUSA-N ciluprevir Chemical compound N([C@@H]1C(=O)N2[C@H](C(N[C@@]3(C[C@H]3\C=C/CCCCC1)C(O)=O)=O)C[C@H](C2)OC=1C2=CC=C(C=C2N=C(C=1)C=1N=C(NC(C)C)SC=1)OC)C(=O)OC1CCCC1 PJZPDFUUXKKDNB-KNINVFKUSA-N 0.000 description 1
229940114081 cinnamate Drugs 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000004891 communication Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
238000003271 compound fluorescence assay Methods 0.000 description 1
238000013170 computed tomography imaging Methods 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000013256 coordination polymer Substances 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
208000029078 coronary artery disease Diseases 0.000 description 1
230000008878 coupling Effects 0.000 description 1
239000007819 coupling partner Substances 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
229940088900 crixivan Drugs 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
208000033679 diabetic kidney disease Diseases 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
108010083141 dipeptidyl carboxypeptidase Proteins 0.000 description 1
229940079593 drug Drugs 0.000 description 1
229940000406 drug candidate Drugs 0.000 description 1
238000011977 dual antiplatelet therapy Methods 0.000 description 1
108010039262 elastatinal Proteins 0.000 description 1
238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
238000000921 elemental analysis Methods 0.000 description 1
229950000234 emricasan Drugs 0.000 description 1
210000003890 endocrine cell Anatomy 0.000 description 1
ZUBDGKVDJUIMQQ-ZTNLKOGPSA-N endothelin i Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CSSC[C@@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-ZTNLKOGPSA-N 0.000 description 1
230000007071 enzymatic hydrolysis Effects 0.000 description 1
238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
238000001952 enzyme assay Methods 0.000 description 1
SRLROPAFMUDDRC-INIZCTEOSA-N ethyl N-benzoyl-L-tyrosinate Chemical compound C([C@@H](C(=O)OCC)NC(=O)C=1C=CC=CC=1)C1=CC=C(O)C=C1 SRLROPAFMUDDRC-INIZCTEOSA-N 0.000 description 1
UKNNCBXEELDDCU-SUJAAXHWSA-N fumagalone Chemical compound O=C[C@@]1(O)CCC(=O)[C@@H](OC)[C@@H]1[C@]1(C)[C@@H](CC=C(C)C)O1 UKNNCBXEELDDCU-SUJAAXHWSA-N 0.000 description 1
NGGMYCMLYOUNGM-CSDLUJIJSA-N fumagillin Chemical compound C([C@H]([C@H]([C@@H]1[C@]2(C)[C@H](O2)CC=C(C)C)OC)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O)C[C@@]21CO2 NGGMYCMLYOUNGM-CSDLUJIJSA-N 0.000 description 1
229960000936 fumagillin Drugs 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
108010031316 furylacryloylalanylarginine Proteins 0.000 description 1
108010039140 furylacryloylalanyllysine Proteins 0.000 description 1
239000003540 gamma secretase inhibitor Substances 0.000 description 1
206010017758 gastric cancer Diseases 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
108010081886 globomycin Proteins 0.000 description 1
235000013905 glycine and its sodium salt Nutrition 0.000 description 1
229930004094 glycosylphosphatidylinositol Natural products 0.000 description 1
NESRXFGQJARQNM-OWYFMNJBSA-N graphinone Chemical compound O=C([C@H]([C@]1(O)[C@]2(C)[C@H](O2)CC=C(C)C)OC)CC[C@@]21CO2 NESRXFGQJARQNM-OWYFMNJBSA-N 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
206010073071 hepatocellular carcinoma Diseases 0.000 description 1
231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
230000003301 hydrolyzing effect Effects 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000001631 hypertensive effect Effects 0.000 description 1
238000010191 image analysis Methods 0.000 description 1
238000011503 in vivo imaging Methods 0.000 description 1
229960001936 indinavir Drugs 0.000 description 1
NUBQKPWHXMGDLP-BDEHJDMKSA-N indinavir sulfate Chemical compound OS(O)(=O)=O.C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 NUBQKPWHXMGDLP-BDEHJDMKSA-N 0.000 description 1
230000003993 interaction Effects 0.000 description 1
229940088976 invirase Drugs 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
229950003188 isovaleryl diethylamide Drugs 0.000 description 1
OSMJFYFZOAVCNP-UHFFFAOYSA-N isovaleryl-L-tyrosyl-L-valyl-DL-tyrosinal Natural products C=1C=C(O)C=CC=1CC(C=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CC(C)C)CC1=CC=C(O)C=C1 OSMJFYFZOAVCNP-UHFFFAOYSA-N 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
108010075606 kynostatin 272 Proteins 0.000 description 1
DAQAKHDKYAWHCG-RWTHQLGUSA-N lactacystin Chemical compound CC(=O)N[C@H](C(O)=O)CSC(=O)[C@]1([C@@H](O)C(C)C)NC(=O)[C@H](C)[C@@H]1O DAQAKHDKYAWHCG-RWTHQLGUSA-N 0.000 description 1
239000003591 leukocyte elastase inhibitor Substances 0.000 description 1
108010052968 leupeptin Proteins 0.000 description 1
229960004525 lopinavir Drugs 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
230000002132 lysosomal effect Effects 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
OCSMOTCMPXTDND-OUAUKWLOSA-N marimastat Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO OCSMOTCMPXTDND-OUAUKWLOSA-N 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
208000031225 myocardial ischemia Diseases 0.000 description 1
IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
SYAOZPXWOOYNES-UHFFFAOYSA-N n-butyryl-L-tyrosyl-L-leucyl-DL-tyrosynal Natural products C=1C=C(O)C=CC=1CC(C=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)CCC)CC1=CC=C(O)C=C1 SYAOZPXWOOYNES-UHFFFAOYSA-N 0.000 description 1
OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
229960000884 nelfinavir Drugs 0.000 description 1
NQHXCOAXSHGTIA-SKXNDZRYSA-N nelfinavir mesylate Chemical compound CS(O)(=O)=O.CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 NQHXCOAXSHGTIA-SKXNDZRYSA-N 0.000 description 1
229960005230 nelfinavir mesylate Drugs 0.000 description 1
210000003061 neural cell Anatomy 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
229940072250 norvir Drugs 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
229960003104 ornithine Drugs 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
108010091212 pepstatin Proteins 0.000 description 1
BWSDNRQVTFZQQD-AYVHNPTNSA-N phosphoramidon Chemical compound O([P@@](O)(=O)N[C@H](CC(C)C)C(=O)N[C@H](CC=1[C]2C=CC=CC2=NC=1)C(O)=O)[C@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@@H]1O BWSDNRQVTFZQQD-AYVHNPTNSA-N 0.000 description 1
108010072906 phosphoramidon Proteins 0.000 description 1
108010066715 piperastatin B Proteins 0.000 description 1
239000013641 positive control Substances 0.000 description 1
108010080180 poststatin Proteins 0.000 description 1
229950000362 pralnacasan Drugs 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
235000019419 proteases Nutrition 0.000 description 1
229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
229950010131 puromycin Drugs 0.000 description 1
238000004445 quantitative analysis Methods 0.000 description 1
108700040249 racecadotril Proteins 0.000 description 1
229960002281 racecadotril Drugs 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
230000036391 respiratory frequency Effects 0.000 description 1
108700016891 retrothiorphan Proteins 0.000 description 1
229950007656 rupintrivir Drugs 0.000 description 1
NGWSFRIPKNWYAO-UHFFFAOYSA-N salinosporamide A Natural products N1C(=O)C(CCCl)C2(C)OC(=O)C21C(O)C1CCCC=C1 NGWSFRIPKNWYAO-UHFFFAOYSA-N 0.000 description 1
230000007017 scission Effects 0.000 description 1
210000004739 secretory vesicle Anatomy 0.000 description 1
238000000926 separation method Methods 0.000 description 1
108010059841 serine carboxypeptidase Proteins 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
210000004872 soft tissue Anatomy 0.000 description 1
239000002904 solvent Substances 0.000 description 1
125000006850 spacer group Chemical group 0.000 description 1
241000894007 species Species 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000001119 stannous chloride Substances 0.000 description 1
235000011150 stannous chloride Nutrition 0.000 description 1
DFVFTMTWCUHJBL-BQBZGAKWSA-N statine Chemical compound CC(C)C[C@H](N)[C@@H](O)CC(O)=O DFVFTMTWCUHJBL-BQBZGAKWSA-N 0.000 description 1
238000003756 stirring Methods 0.000 description 1
201000011549 stomach cancer Diseases 0.000 description 1
239000012089 stop solution Substances 0.000 description 1
210000001768 subcellular fraction Anatomy 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 description 1
210000001550 testis Anatomy 0.000 description 1
150000003573 thiols Chemical class 0.000 description 1
WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
XCHUIXZPWRRVAH-RRAJOLSVSA-M trimethyl-[4-[(e)-3-(4-methyl-2-oxochromen-7-yl)oxy-3-oxoprop-1-enyl]phenyl]azanium;chloride Chemical compound [Cl-].C1=CC=2C(C)=CC(=O)OC=2C=C1OC(=O)\C=C\C1=CC=C([N+](C)(C)C)C=C1 XCHUIXZPWRRVAH-RRAJOLSVSA-M 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
108010030360 tyropeptin A Proteins 0.000 description 1
108010030358 tyropeptin B Proteins 0.000 description 1
108010081797 tyrostatin Proteins 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
229940099039 velcade Drugs 0.000 description 1
229940023080 viracept Drugs 0.000 description 1
238000005406 washing Methods 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011592 zinc chloride Substances 0.000 description 1
235000005074 zinc chloride Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0495—Pretargeting
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Optics & Photonics (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Physics & Mathematics (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Plural Heterocyclic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

AU2007289168A 2006-08-29 2007-08-29 Radioimaging moieties coupled to peptidase-binding moieties for imaging tissues and organs that express peptidases Abandoned AU2007289168A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US82388406P	2006-08-29	2006-08-29
US60/823,884		2006-08-29
PCT/US2007/077161 WO2008028000A2 (fr)	2006-08-29	2007-08-29	Fragments de radio-imagerie couplés à des fragments de liaison aux peptidases permettant d'imager des tissus et des organes exprimant des peptidases

Publications (1)

Publication Number	Publication Date
AU2007289168A1 true AU2007289168A1 (en)	2008-03-06

Family

ID=39136854

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2007289168A Abandoned AU2007289168A1 (en)	2006-08-29	2007-08-29	Radioimaging moieties coupled to peptidase-binding moieties for imaging tissues and organs that express peptidases

Country Status (8)

Country	Link
US (1)	US20080213172A1 (fr)
EP (1)	EP2061518A4 (fr)
JP (1)	JP2010502646A (fr)
CN (1)	CN101594886A (fr)
AU (1)	AU2007289168A1 (fr)
BR (1)	BRPI0716368A2 (fr)
CA (1)	CA2661979A1 (fr)
WO (1)	WO2008028000A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2823826A3 (fr)	2008-01-09	2015-03-25	Molecular Insight Pharmaceuticals, Inc.	Inhibiteurs d'anhydrase carbonique IX
RU2011116223A (ru) *	2008-09-25	2012-10-27	Моликьюлар Инсайт Фармасьютикалз, Инк. (Us)	Селективные ингибиторы сепразы
WO2010065906A2 (fr)	2008-12-05	2010-06-10	Molecular Insight Pharmaceuticals, Inc.	Produits radiopharmaceutiques spécifiques de ca-ix pour le traitement et l'imagerie de cancer
WO2010065899A2 (fr)	2008-12-05	2010-06-10	Molecular Insight Pharmaceuticals, Inc.	Complexes de technétium- et rhénium-bis (hétéroaryles) et leurs procédés d'utilisation
CA2745918C (fr) *	2008-12-05	2017-10-10	Molecular Insight Pharmaceuticals, Inc.	Complexes de technetium- et rhenium-bis (heteroaryles) et leurs procedes d'utilisation
US8465725B2 (en)	2009-06-15	2013-06-18	Molecular Insight Pharmaceuticlas, Inc.	Process for production of heterodimers of glutamic acid
EP2707394A4 (fr) *	2011-05-12	2015-06-24	Metallopharm Llc	Métallo-médicaments possédant des propriétés pharmacologiques améliorées, et leurs procédés de production et d'utilisation
WO2013007660A1 (fr) *	2011-07-08	2013-01-17	Biosynthema Inc.	Ciblage in vivo amélioré de peptides radiomarqués au moyen d'inhibiteurs enzymatiques
EP2800471A4 (fr)	2012-01-06	2015-11-04	Molecular Insight Pharm Inc	Complexe métalliques de poly (carboxyl) amine contenant des ligands ayant une affinité pour l'anhydrase carbonique ix
EP2894477A4 (fr) *	2012-09-05	2016-07-20	Wako Pure Chem Ind Ltd	Procédé de dépistage du cancer du sein
CN103006632B (zh) *	2012-12-31	2015-04-22	苏州大学	化合物Clik148在制备治疗脑血管疾病的药物中的应用
JP6468602B2 (ja)	2013-01-14	2019-02-13	モレキュラインサイトファーマシューティカルズインコーポレイテッド	トリアジン系放射性医薬品及び放射線造影剤
WO2018111989A1 (fr)	2016-12-14	2018-06-21	Purdue Research Foundation	Imagerie et thérapie ciblées par une protéine d'activation des fibroblastes (fap)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4741900A (en) *	1982-11-16	1988-05-03	Cytogen Corporation	Antibody-metal ion complexes
US5601801A (en) *	1994-08-02	1997-02-11	Merck Frosst Canada, Inc.	Radiolabelled angiotensin converting enzyme inhibitors
US6589503B1 (en) *	1998-06-20	2003-07-08	Washington University	Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
US7045532B2 (en) *	1999-04-30	2006-05-16	Millennium Pharmaceuticals, Inc.	ACE-2 modulating compounds and methods of use thereof
CA2448051A1 (fr) *	2001-06-04	2002-12-12	Human Genome Sciences, Inc.	Procedes et compositions permettant la modulation de l'activite de l'enzyme de conversion de l'angiotensine-2
EP1401479B1 (fr) *	2001-06-04	2007-04-18	The General Hospital Corporation	Detection et therapie de plaques vulnerables a l'aide de composes photodynamiques
JP4846199B2 (ja) *	2002-03-11	2011-12-28	モレキュラインサイトファーマシューティカルズインコーポレイテッド	テクネチウム−ジビリジン複合体、およびその使用法
WO2003084575A1 (fr) *	2002-04-01	2003-10-16	Biostream, Inc.	Agents d'imagerie d'acides gras pendants
JP2007525452A (ja) *	2003-04-15	2007-09-06	マリンクロッド・インコーポレイテッド	Ｒｅおよびｔｃトリカルボニル錯体のための配位子を含有する二官能性三座ピラゾリル

2007
- 2007-08-29 US US11/847,276 patent/US20080213172A1/en not_active Abandoned
- 2007-08-29 CA CA002661979A patent/CA2661979A1/fr not_active Abandoned
- 2007-08-29 EP EP07814560A patent/EP2061518A4/fr not_active Withdrawn
- 2007-08-29 AU AU2007289168A patent/AU2007289168A1/en not_active Abandoned
- 2007-08-29 JP JP2009526898A patent/JP2010502646A/ja active Pending
- 2007-08-29 BR BRPI0716368-1A2A patent/BRPI0716368A2/pt not_active IP Right Cessation
- 2007-08-29 CN CNA2007800403852A patent/CN101594886A/zh active Pending
- 2007-08-29 WO PCT/US2007/077161 patent/WO2008028000A2/fr not_active Ceased

Also Published As

Publication number	Publication date
BRPI0716368A2 (pt)	2013-10-01
US20080213172A1 (en)	2008-09-04
EP2061518A4 (fr)	2011-05-11
EP2061518A2 (fr)	2009-05-27
WO2008028000A3 (fr)	2008-08-21
JP2010502646A (ja)	2010-01-28
CN101594886A (zh)	2009-12-02
WO2008028000A2 (fr)	2008-03-06
CA2661979A1 (fr)	2008-03-06

Publication	Publication Date	Title
US20080213172A1 (en)	2008-09-04	Radioimaging moieties coupled to peptidease-binding moieties for imaging tissues and organs that express peptidases
US11298341B2 (en)	2022-04-12	PSMA binding ligand-linker conjugates and methods for using
JP6177832B2 (ja)	2017-08-09	アルギナーゼ阻害剤および使用方法
US7060248B2 (en)	2006-06-13	Matrix metalloproteinase inhibitors
Machulkin et al.	2016	Small-molecule PSMA ligands. Current state, SAR and perspectives
V. Ferraris et al.	2012	Structure-activity relationships of glutamate carboxypeptidase II (GCPII) inhibitors
Nedrow‐Byers et al.	2012	A phosphoramidate‐based prostate‐specific membrane antigen‐targeted SPECT agent
CN117642190A (zh)	2024-03-01	缀合有三接头的二聚体标记前体和由其衍生的放射性示踪剂
US20050106100A1 (en)	2005-05-19	Compounds containing matrix metalloproteinase substrates and methods of their use
HUT77137A (hu)	1998-03-02	Radionuklid-kelátképző peptidszármazékok
Edem et al.	2014	Synthesis and evaluation of radioiodinated acyloxymethyl ketones as activity-based probes for cathepsin B
Wiele et al.	2006	Update: Imaging Probes Targeting Matrix Metalloproteinases
US20120251459A1 (en)	2012-10-04	Specific inhibitors and active site probes for legumain
US20070014721A1 (en)	2007-01-18	Hydrazide conjugates as imaging agents
EP4637826A1 (fr)	2025-10-29	Composés conjugués et leur utilisation dans le traitement et le diagnostic du cancer
KR101861025B1 (ko)	2018-05-24	영상화 제제로서의 ｎ-알콕시아미드 접합체
Agost‐Beltrán et al.	2025	Profiling Cysteine Proteases Activities in Neuroinflammatory Cells
WO2011091973A1 (fr)	2011-08-04	5-nitro-8-hydroxyquinoléines en tant qu'inhibiteurs de la cathepsine b
CA3217281A1 (fr)	2022-11-03	Radiopharmaceutiques a base d'acide ((r)?1?((6?hydrazynylnicotinoyl)?d?alanyl)pyrrolydin-2-yl)boronique (hynic-ifap) pour la detection de la surexpression de la proteine d'activation de fibroblaste
Hadzima	2025	Synthesis of inhibitors and substrates for the inhibition, visualization and targeting of proteases
Lodhi	2019	Synthesis and In Vivo Biological Evaluation of 99mTc (I) Tri-carbonyl Based Radiopharmaceuticals for SPECT Imaging
KR20250011148A (ko)	2025-01-21	전립선-특이적 막 항원(psma) 리간드
Gonçalves et al.	2018	Chemical Probes Targeting Proteases for Imaging and Diagnostics in Cancer
Edem	2011	PREPARATION AND EVALUATION OF PEPTIDYL ACYLOXYMETHYL KETONES FOR CATHEPSIN B IMAGING
HK1200823B (en)	2019-06-28	N-alkoxyamide conjugates as imaging agents

Legal Events

Date	Code	Title	Description
2014-03-27	MK4	Application lapsed section 142(2)(d) - no continuation fee paid for the application